Why there’s little chance we’ll have coronavirus vaccine data in October, according to JPMorgan

Welcome to Business Insider‘s daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.

Hello,

Today in healthcare news: JPMorgan ran 10,000 simulations that show why an October coronavirus vaccine is unlikely, 10 healthcare stocks to bet on, according to Morgan Stanley, and why we’ll likely not have enough vaccines for everybody until 2024.

JPMorgan sees a ‘low probability’ for coronavirus vaccine data in October after running 10,000 simulations on how the studies will play out

• JPMorgan sees a “low probability” of having coronavirus vaccine data in October.
• The biotech analysts ran 10,000 simulations across 10 scenarios on how studies for two leading vaccine candidates could play out.

Read the full story from Andrew Dunn here>>

Morgan Stanley handpicked the 10 best healthcare stocks to buy now as investors brace for a major election and the potential for another coronavirus surge

• Morgan Stanley recommended 10 stocks that they think will perform well as the US faces its next presidential election and as the world recovers from the coronavirus pandemic.
• Analysts recommended six pharmaceutical stocks — despite political rhetoric bashing drug prices. 
• Here are the top healthcare picks. 

Read the full story from Kimberly Leonard here>>

We won't have enough COVID-19 vaccine for everybody until 2024, warns world's largest vaccine producer

• There will not be enough doses of a COVID-19 vaccine to reach everyone worldwide until at least 2024, according to the CEO of the world's largest vaccine producer.
• Pharmaceutical companies are not increasing production quickly enough to vaccinate everyone before 2024, Adar Poonawalla, CEO of the Serum Institute of India, told the Financial Times.

Read the full story from Kate Duffy here>>

More stories we're reading:

• GoodRx and its investors are looking to raise about $900 million as the company goes public (Business Insider)
• Trump officials interfered with CDC reports (Politico)
• A Trump health aide went on a conspiracy-filled Facebook video rant  (The New York Times)
• The 10 most promising coronavirus treatments that could help curb the pandemic, even without a vaccine (Business Insider)

See you tomorrow! In the meantime, subscribe to this newsletter here. 

- Lydia